All In MedTech

Device Trial Radar · NCT04374916

Evaluation of a New Predictive Test of Preterm Birth in Case of Threatened Preterm Labor

Last checked: Nov 20, 2026Latest source record: Aug 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Aug 11, 2020

Primary completion

Apr 4, 2025

Study completion Sep 2026

Sponsor

Lead sponsor
University Hospital, Strasbourg, FranceAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 5, 2020

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated device
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Threatened preterm labor (TPL) is defined by cervical changes and regular and painful uterine contractions occurring between 24 and 36 + 6 weeks of gestation that may or may not lead to premature labor and delivery. There is no reliable way to predict preterm delivery. The study's hypothesis is that the Premaquick® test can improve the prediction of preterm delivery. The investigators also want to compare this test with the Partosure® (Placental alpha microglobulin-1) test.

Conditions

  • Threatened Preterm Labor
  • Preterm Delivery

Interventions

  • Premaquick®Device

    Vaginal secretions are collected prior to any vaginal or endovaginal ultrasound examination to avoid false positives, with the nylon swab provided with the test (placed in the posterior fornix of the vagina for 10 seconds).Then the samples are tested with the Premaquick test. Results are obtained in 10 minutes.

  • PARTOSURE®Device

    An immunochromatographic test wich determines the qualitative in vitro detection of placental alpha microglobulin-1 (PAMG-1) in cervico-vaginal secretions.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The primary outcome measure will be the occurrence of a premature delivery within 7 days after patient's inclusion.Time frame: The outcome measure is assessed at visit 2 (day 7), 7 days after the inclusion visit.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hôpitaux Universitaires de Strasbourg

    Strasbourg, France · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.